Business Development Dermatology Development Hormones 
The Pharma Data
AUGUST 3, 2021
billion in acquired in-process research & development (acquired IPR&D) associated with our acquisition of Five Prime Therapeutics, partially offset by increased revenues. We expect that recovery in the dermatology segment will continue to progress over the coming quarters. GAAP earnings per share (EPS) decreased 73% to $0.81
XTalks
AUGUST 2, 2023
is a global pharmaceutical company, working across both developed and emerging markets. They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. Pfizer Inc.
Expert insights. Personalized for you.
52 
Let's personalize your content